Skip to content
stoqly
en

Languages

Figures come from SEC filings, which are in English. Company and industry names stay as filed.

$ USD

Popular

All currencies

Data is in US dollars, converted at the ECB reference rate of Oct 23, 2026.

enGene Therapeutics Inc.

ENGN Nasdaq Biological Products, (No Diagnostic Substances) Financials FY2022–FY2025

Download report 3-page PDF: the company, its results and charts with peers.

Last close Β· Oct 23, 2026

$1.56

1.3%

What enGene Therapeutics Inc. does

ENGN Β· Biological Products, (No Diagnostic Substances)

From its latest annual report

No business description yet.

Filing details

Legal name
enGene Therapeutics Inc.
Fiscal year ends
October 31, 2025
Latest annual report
10-K Β· Dec 22, 2025
Accession Β· CIK
0001193125-25-328743 Β· 0001980845

KIRA’s summary AI analyst

Hi! I read enGene Therapeutics Inc.’s latest annual report (fiscal 2025). Here is what stands out:

2 to watch

enGene Therapeutics Inc. in 30 seconds

Good So-so Weak

Weak

Does it make a profit?

βˆ’$117M

No. It lost money last year.

For information

How is the share priced?

0.6x

One share costs 0.6 times its yearly profit per share.

Rules of thumb on reported numbers. A starting point, not a recommendation.

Key numbers, fiscal 2025

Market cap Last close times the latest diluted share count, so it is approximate.
$109M
Oct 23 close
P/E Last close divided by diluted earnings per share over the last four quarters.
0.6x
On $2.43 EPS (TTM)

Revenue

Total sales reported in the income statement.

See the full section β†’

Operating margin

Operating income as a share of revenue.

See the full section β†’

Net income

Profit after all expenses, interest and tax.

KIRA Β· enGene Therapeutics Inc. lost $117M in fiscal 2025. From fiscal 2022 to 2025, diluted EPS grew βˆ’62.7% a year.

See the full section β†’

Free cash flow

Cash from operations minus capital spending.

KIRA Β· Free cash flow was βˆ’$101M in fiscal 2025, β€” of revenue.

See the full section β†’

Return on capital

After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.

See the full section β†’
Charts by

Sales and profit

Is it selling more, and how much does it keep?

Results dates

In plain words: Every quarter, companies publish how much they sold and earned. These are the days enGene Therapeutics Inc. did it, and the next one. Share prices often move a lot on those days.

Next results

December 21, 2026

Monday Β· in 57 days

Time
After the market closes
Covers
Period ended Oct 31, 2026
Source
Stoqly estimate

Estimated from the same quarter last year. It will be replaced by the announced date once there is one.

See who else reports that week β†’
Date Results for Time Source
Sep 8, 2026 Q3 '26 Before the market opens 8-K β†—
Jun 13, 2026 Q2 '26 Time not announced 8-K β†—
Mar 9, 2026 Q1 '26 Before the market opens 8-K β†—
Dec 22, 2025 Q4 '25 After the market closes 8-K β†—
Sep 11, 2025 Q3 '25 After the market closes 8-K β†—
Jun 12, 2025 Q2 '25 Before the market opens 8-K β†—
Mar 10, 2025 Q1 '25 After the market closes 8-K β†—
Dec 19, 2024 Q4 '24 After the market closes 8-K β†—

From SEC filings: the results press release (8-K) or, without one, the quarterly or annual report.

Revenue and margins

In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).

Revenue

Margins, % of revenue

Gross Operating Net FCF

Net income and earnings per share

KIRA Β· enGene Therapeutics Inc. lost $117M in fiscal 2025. From fiscal 2022 to 2025, diluted EPS grew βˆ’62.7% a year.

Loss periods are shown in red.

In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.

Net income

Net income

Diluted EPS

Diluted EPS

Cash and shareholders

How much cash comes in, and where does it go?

Cash flow

KIRA Β· Free cash flow was βˆ’$101M in fiscal 2025, β€” of revenue.

Cash from operations minus capital spending.

In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.

Free cash flow

Free cash flow

Cash from operations vs capital spending

Cash from operations Capital spending

Cash from operations vs capital spending

Cash from operations Capital spending

Dividends, buybacks and share count

In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).

Dividends and buybacks

Dividends Buybacks

Diluted shares outstanding (annual)

Insider trades

KIRA Β· No open-market insider trades in the last 12 months.

Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. β€œPlan” marks trades under a pre-arranged Rule 10b5-1 plan.

In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.

Bought, 12 months

$0.0M

0 insiders

Sold, 12 months

$0.0M

0 insiders

Of sales under plans

β€”

$0.0M

No open-market insider trades in the last 12 months.

Financial health

Can it carry its debts, and how well does it use its money?

Balance sheet

Cash, debt and the ratios that show how comfortably enGene Therapeutics Inc. can carry it.

In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.

Cash vs debt (incl. leases)

Cash Debt
Fiscal year endFY22FY23FY24FY25
Cash and short-term investments $20.4M$81.5M$238M$194M
Interest coverage βˆ’13.7xβˆ’5.3xβˆ’22.3xβˆ’41.1x
Current ratio 4.4x16.3x16.9x6.3x
Quick ratio 4.4x16.3x16.9x6.3x
Total assets $23.9M$87.0M$311M$221M
Total liabilities $47.4M$14.5M$38.6M$53.8M
Shareholders' equity βˆ’$76.6M$72.5M$273M$168M
Net debt (βˆ’ = net cash) β€”β€”β€”β€”

Returns on capital

After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.

In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.

Return on capital, equity and assets (annual)

Return on capital Return on equity Return on assets

Piotroski F-score

Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.

In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.

TestFY22FY23FY24FY25
Net income is positive βœ• βœ• βœ• βœ•
Cash from operations is positive βœ• βœ• βœ• βœ•
Return on assets rose β€” βœ• βœ“ βœ•
Cash from operations exceeds net income βœ“ βœ“ βœ“ βœ“
Debt fell relative to assets β€” β€” β€” β€”
Current ratio rose β€” βœ“ βœ“ βœ•
Share count didn't rise β€” βœ• βœ• βœ•
Gross margin rose β€” β€” β€” β€”
Revenue rose relative to assets β€” β€” β€” β€”
F-score β€” / 3β€” / 6β€” / 6β€” / 6
Accruals ratio βˆ’28.7%βˆ’135.6%βˆ’3.4%βˆ’6.8%
Altman Z'' βˆ’15.951.818.31βˆ’0.92

All figures

Every number, year by year.

4 years of figures

Amounts in USD. Hover a ratio’s name for its definition.

In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.

Download CSV
Fiscal yearFY22FY23FY24FY25
Income statement
Research and development $15.5M $16.5M $38.3M $94.5M
Operating income βˆ’$19.4M βˆ’$26.1M βˆ’$62.3M βˆ’$123M
Interest expense $1.4M $5.0M $2.8M $3.0M
Pretax income βˆ’$24.4M βˆ’$99.9M βˆ’$55.2M βˆ’$117M
Income tax $0.0M $0.0M βˆ’$0.0M $0.0M
Net income βˆ’$24.5M βˆ’$99.9M βˆ’$55.1M βˆ’$117M
Net income to common βˆ’$29.0M βˆ’$105M βˆ’$55.1M βˆ’$117M
Diluted EPS $44.30 $151.22 $1.46 $2.29
Diluted shares 0.00B 0.00B 0.04B 0.05B
Cash flow
Cash from operations βˆ’$17.6M βˆ’$24.7M βˆ’$48.3M βˆ’$99.2M
Capital expenditure $0.2M $0.3M $0.9M $1.5M
Free cash flow βˆ’$17.7M βˆ’$25.1M βˆ’$49.2M βˆ’$101M
Depreciation and amortization $0.2M $0.2M $0.3M $0.5M
Stock-based compensation $0.1M $3.5M $5.3M $9.6M
Dividends paid β€” $0.0M β€” β€”
Dividends and buybacks β€” $0.0M β€” β€”
Balance sheet
Cash and short-term investments $20.4M $81.5M $238M $194M
Current assets $22.6M $85.4M $247M $201M
Current liabilities $5.1M $5.3M $14.7M $32.0M
Property and equipment, net $0.4M $0.6M $1.2M $2.5M
Total assets $23.9M $87.0M $311M $221M
Total liabilities $47.4M $14.5M $38.6M $53.8M
Shareholders' equity βˆ’$76.6M $72.5M $273M $168M
Returns
Return on capital employed βˆ’103.3% βˆ’31.9% βˆ’21.0% βˆ’65.0%
Return on equity β€” β€” βˆ’32.0% βˆ’53.3%
Return on assets βˆ’102.3% βˆ’180.2% βˆ’27.7% βˆ’44.0%
Return on tangible equity β€” βˆ’144.5% βˆ’20.2% βˆ’69.9%
Growth
EPS growth β€” 241.4% βˆ’99.0% 56.8%
Share count change β€” 5.7% 5,355.1% 35.3%
Financial health
Interest coverage βˆ’13.7x βˆ’5.3x βˆ’22.3x βˆ’41.1x
Current ratio 4.4x 16.3x 16.9x 6.3x
Quick ratio 4.4x 16.3x 16.9x 6.3x
Quality scores
Altman Z'' βˆ’16.0 1.8 8.3 βˆ’0.9
Accruals ratio βˆ’28.7% βˆ’135.6% βˆ’3.4% βˆ’6.8%

Source: SEC EDGAR XBRL filings (CIK 0001980845). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β€” not investment advice. Check the original filings before relying on any figure.

↑ ↓ to move Β· ↡ to open